TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder
Brief Summary: The aim of the study was to investigate if the addition of cognitive behavioural therapy to treatment as usual (CBT plus TAU) in participants with borderline personality disorder would decrease the number of participants with emergency (i.e. unplanned) psychiatric or accident and emergency room contact or episode of deliberate self-harm over twelve months treatment and twelve months follow-up, compared with treatment as usual (TAU). The study also examined whether CBT plus TAU would lead to superior improvement in quality of life, social, cognitive and mental health functioning than TAU alone.


Options:
A: Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): N/A
B: Arm Label: Short-term MBT; Type: EXPERIMENTAL; Interventions: Other: Short-term MBT | Arm Label: Long-term MBT; Type: ACTIVE_COMPARATOR; Interventions: Other: Long-term MBT | Intervention Type: OTHER; Name: Short-term MBT; Assigned to Arm(s): Short-term MBT | Intervention Type: OTHER; Name: Long-term MBT; Assigned to Arm(s): Long-term MBT
C: Arm Label: cognitive remediation; Type: EXPERIMENTAL; Interventions: Other: cognitive remediation | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Other: Psychoeducation | Intervention Type: OTHER; Name: cognitive remediation; Assigned to Arm(s): cognitive remediation | Intervention Type: OTHER; Name: Psychoeducation; Assigned to Arm(s): Psychoeducation
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BOSCOT: A Randomised Control Trial of Cognitive Behavioural Therapy Plus Treatment as Usual Versus Treatment as Usual in the Treatment of Borderline Personality Disorder
Brief Summary: The aim of the study was to investigate if the addition of cognitive behavioural therapy to treatment as usual (CBT plus TAU) in participants with borderline personality disorder would decrease the number of participants with emergency (i.e. unplanned) psychiatric or accident and emergency room contact or episode of deliberate self-harm over twelve months treatment and twelve months follow-up, compared with treatment as usual (TAU). The study also examined whether CBT plus TAU would lead to superior improvement in quality of life, social, cognitive and mental health functioning than TAU alone.


Options:
A: Arm Label: I ziprasidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ziprasidone | Arm Label: II placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ziprasidone; Assigned to Arm(s): I ziprasidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): II placebo
B: Arm Label: dialectical behavior therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavior therapy | Arm Label: treatment as usual; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT | Arm Label: Receiving no treatment at all; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialectical behavior therapy; Assigned to Arm(s): dialectical behavior therapy | Intervention Type: OTHER; Name: Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT; Assigned to Arm(s): treatment as usual
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: General Psychiatric Management | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical Behaviour Therapy | Intervention Type: BEHAVIORAL; Name: General Psychiatric Management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Dialectical Behaviour Therapy; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy, Other: Treatment as usual | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4
Brief Summary: The purpose of this study is to evaluate the absolute (versus placebo) and relative (one vaccine compared to the other) efficacies of the live attenuated and inactivated influenza vaccines in preventing laboratory confirmed symptomatic influenza caused by circulating strains whether similar or dissimilar to strains included in the vaccines.


Options:
A: Arm Label: cohort I; Type: OTHER; Interventions: Biological: GHB01L1 | Arm Label: cohort II; Type: OTHER; Interventions: Biological: GHB01L1 | Arm Label: cohort III; Type: OTHER; Interventions: Biological: GHB01L1 | Arm Label: cohort IV; Type: OTHER; Interventions: Biological: GHB01L1 | Arm Label: cohort V; Type: OTHER; Interventions: Biological: GHB01L1 | Intervention Type: BIOLOGICAL; Name: GHB01L1; Assigned to Arm(s): cohort I, cohort II, cohort III, cohort IV, cohort V
B: Arm Label: TIV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fluzone | Arm Label: LAIV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Flumist | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Physiologic saline | Intervention Type: BIOLOGICAL; Name: Fluzone; Assigned to Arm(s): TIV | Intervention Type: BIOLOGICAL; Name: Flumist; Assigned to Arm(s): LAIV | Intervention Type: OTHER; Name: Physiologic saline; Assigned to Arm(s): Placebo
C: Intervention Type: BIOLOGICAL; Name: pneumococcal polysaccharide and protein conjugate vaccines; Assigned to Arm(s): N/A
D: Arm Label: 6-23 months; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 2-8 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 9-17 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 18-44 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 45-60 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: >60 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Intervention Type: OTHER; Name: This is non-intervention observational study; Assigned to Arm(s): 18-44 years, 2-8 years, 45-60 years, 6-23 months, 9-17 years, >60 years

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extrapulmonary Interventional Ventilatory Support for Lung Protection in Severe Acute Respiratory Distress - a Prospective Randomized Multi Centre Study
Brief Summary: A prospective, randomized study will be performed investigating the effects of a pumpless extracorporeal interventional lung assist \[iLA\] on the implementation of a lung-protective ventilatory strategy in patients with acute respiratory distress syndrome \[ARDS\] with a PaO2/FiO2 ratio \< 200. The duration of ventilation, intensive care and hospital stay and in-hospital mortality will be investigated.


Options:
A: Arm Label: CCPR protocol; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ECPR protocol; Type: EXPERIMENTAL; Interventions: Procedure: Extracorporeal cardiopulmonary resuscitation (ECPR) | Intervention Type: PROCEDURE; Name: Extracorporeal cardiopulmonary resuscitation (ECPR); Assigned to Arm(s): ECPR protocol
B: Arm Label: Moderate hypothermia; Type: EXPERIMENTAL; Interventions: Other: moderate hypothermia | Arm Label: Normothermia; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: moderate hypothermia; Assigned to Arm(s): Moderate hypothermia
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: lung protective ventilation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: lung protective ventilation | Intervention Type: OTHER; Name: lung protective ventilation; Assigned to Arm(s): 1, 2
D: Arm Label: Extra-Corporal Life Support (ECLS); Type: ACTIVE_COMPARATOR; Interventions: Device: Extra-Corporal Life Support (ECLS) | Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Extra-Corporal Life Support (ECLS); Assigned to Arm(s): Extra-Corporal Life Support (ECLS)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Swiss Dark Chocolate on Endothelial and Baroreceptor Function and Markers of Inflammation in Patients With Chronic Heart Failure
Brief Summary: The aim of the present study is to investigate whether in patients with chronic heart failure endothelial dysfunction and baroreceptor function is altered by ingestion of a flavonoid-rich dark chocolate in comparison to placebo chocolate (Nestlé Placebo Chocolate) on top of standard medication.

Moreover, we will evaluate the effect of chocolate on oxidative stress, platelet adhesion as well as systemic inflammatory response such as C-reactive protein and pro-inflammatory cytokines in patients with chronic heart failure.


Options:
A: Intervention Type: DRUG; Name: dark chocolate; Assigned to Arm(s): N/A
B: Arm Label: Intervention A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Flavonoid enrichment (cocoa / soy compounds) | Arm Label: Intervention B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Flavonoid enrichment (cocoa / soy compounds) | Intervention Type: DIETARY_SUPPLEMENT; Name: Flavonoid enrichment (cocoa / soy compounds); Assigned to Arm(s): Intervention A | Intervention Type: DIETARY_SUPPLEMENT; Name: Flavonoid enrichment (cocoa / soy compounds); Assigned to Arm(s): Intervention B
C: Arm Label: Cocoa Flavanol intake escalation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Mars Cocoa Extract Capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Mars Cocoa Extract Capsules; Assigned to Arm(s): Cocoa Flavanol intake escalation
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Nestlé Noir intense 40 grx2 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Nestlé Placebo Chocolate 40 grx2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Nestlé Noir intense 40 grx2; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Nestlé Placebo Chocolate 40 grx2; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial.
Brief Summary: This clinical trial was conducted in a population where tympanic membrane perforation occurs in 60% infants in the first year of life. Nasopharyngeal colonisation (nasal contamination) with pathogenic bacteria occurs within weeks of life and predicts persistent middle ear infection throughout childhood. The trial aimed to assess whether twice daily antibiotics commencing at first detection of middle ear effusion would cure the infection and/or prevent disease progression, compared to placebo.

The study was conducted in three remote Aboriginal communities in the Northern Territory of Australia. The annual birth cohort was 45.

Aboriginal infants were seen as soon as possible after birth, and at 2 weekly intervals until middle ear effusion was detected by pneumatic otoscopy and tympanometry. Following consent, infants were randomised to either amoxycillin(50 mg/kg/d BD) or placebo equivalent for up to 24 weeks, or until normal middle ear status was detected at 2 consecutive monthly scheduled examinations. At monthly examinations the infant also had a general health check, parents were interviewed, child's medical record was reviewed, and nasopharyngeal swabs were collected.


Options:
A: Intervention Type: PROCEDURE; Name: adenoidectomy and tymapanostomy; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo equivalent to amoxycillin | Intervention Type: DRUG; Name: Amoxycillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo equivalent to amoxycillin; Assigned to Arm(s): 2
D: Arm Label: Triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone acetonide nasal spray | Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Drug: Placebo nasal spray | Intervention Type: DRUG; Name: Triamcinolone acetonide nasal spray; Assigned to Arm(s): Triamcinolone acetonide | Intervention Type: DRUG; Name: Placebo nasal spray; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial.
Brief Summary: This clinical trial was conducted in a population where tympanic membrane perforation occurs in 60% infants in the first year of life. Nasopharyngeal colonisation (nasal contamination) with pathogenic bacteria occurs within weeks of life and predicts persistent middle ear infection throughout childhood. The trial aimed to assess whether twice daily antibiotics commencing at first detection of middle ear effusion would cure the infection and/or prevent disease progression, compared to placebo.

The study was conducted in three remote Aboriginal communities in the Northern Territory of Australia. The annual birth cohort was 45.

Aboriginal infants were seen as soon as possible after birth, and at 2 weekly intervals until middle ear effusion was detected by pneumatic otoscopy and tympanometry. Following consent, infants were randomised to either amoxycillin(50 mg/kg/d BD) or placebo equivalent for up to 24 weeks, or until normal middle ear status was detected at 2 consecutive monthly scheduled examinations. At monthly examinations the infant also had a general health check, parents were interviewed, child's medical record was reviewed, and nasopharyngeal swabs were collected.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo equivalent to amoxycillin | Intervention Type: DRUG; Name: Amoxycillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo equivalent to amoxycillin; Assigned to Arm(s): 2
B: Arm Label: Ventilation tube treatment; Type: EXPERIMENTAL; Interventions: Device: Ventilation tube treatment | Arm Label: Conservative treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Ventilation tube treatment; Assigned to Arm(s): Ventilation tube treatment
C: Arm Label: Wait and watch (Group D); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Mometasone spray (Group B); Type: EXPERIMENTAL; Interventions: Drug: Mometasone 50 Mcg/Inh Nasal Spray | Arm Label: antibiotic + histaminic + oxymetazoline drops (Group A); Type: EXPERIMENTAL; Interventions: Drug: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%) | Arm Label: Oral steroid (Group C); Type: EXPERIMENTAL; Interventions: Drug: Steroid Drug (prednisolone) | Intervention Type: DRUG; Name: Mometasone 50 Mcg/Inh Nasal Spray; Assigned to Arm(s): Mometasone spray (Group B) | Intervention Type: DRUG; Name: Antibiotics + Antihistamine (levocetirizine) + Nasal decongestants (Oxymetazoline 0.025%); Assigned to Arm(s): antibiotic + histaminic + oxymetazoline drops (Group A) | Intervention Type: DRUG; Name: Steroid Drug (prednisolone); Assigned to Arm(s): Oral steroid (Group C)
D: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial.
Brief Summary: This clinical trial was conducted in a population where tympanic membrane perforation occurs in 60% infants in the first year of life. Nasopharyngeal colonisation (nasal contamination) with pathogenic bacteria occurs within weeks of life and predicts persistent middle ear infection throughout childhood. The trial aimed to assess whether twice daily antibiotics commencing at first detection of middle ear effusion would cure the infection and/or prevent disease progression, compared to placebo.

The study was conducted in three remote Aboriginal communities in the Northern Territory of Australia. The annual birth cohort was 45.

Aboriginal infants were seen as soon as possible after birth, and at 2 weekly intervals until middle ear effusion was detected by pneumatic otoscopy and tympanometry. Following consent, infants were randomised to either amoxycillin(50 mg/kg/d BD) or placebo equivalent for up to 24 weeks, or until normal middle ear status was detected at 2 consecutive monthly scheduled examinations. At monthly examinations the infant also had a general health check, parents were interviewed, child's medical record was reviewed, and nasopharyngeal swabs were collected.


Options:
A: Arm Label: Montelukast; Type: EXPERIMENTAL; Interventions: Drug: Monteleukast | Arm Label: Mometasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mometasone | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Monteleukast; Assigned to Arm(s): Montelukast | Intervention Type: DRUG; Name: Mometasone; Assigned to Arm(s): Mometasone
B: Intervention Type: PROCEDURE; Name: Insertion of tympanostomy tubes; Assigned to Arm(s): N/A
C: Arm Label: Ventilation tube treatment; Type: EXPERIMENTAL; Interventions: Device: Ventilation tube treatment | Arm Label: Conservative treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Ventilation tube treatment; Assigned to Arm(s): Ventilation tube treatment
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo equivalent to amoxycillin | Intervention Type: DRUG; Name: Amoxycillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo equivalent to amoxycillin; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Safety and Reactogenicity of FluBlok, Trivalent Recombinant Influenza Vaccine, and Comparison of the Immunogenicity, Efficacy and Effectiveness of FluBlok to a Licensed Egg-Grown Influenza Vaccine in Adults Aged 50 to 64
Brief Summary: The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.


Options:
A: Arm Label: FluBlok; Type: EXPERIMENTAL; Interventions: Biological: FluBlok Influenza Vaccination | Arm Label: TIV (Fluzone); Type: ACTIVE_COMPARATOR; Interventions: Biological: TIV (Fluzone) Influenza Vaccination | Intervention Type: BIOLOGICAL; Name: FluBlok Influenza Vaccination; Assigned to Arm(s): FluBlok | Intervention Type: BIOLOGICAL; Name: TIV (Fluzone) Influenza Vaccination; Assigned to Arm(s): TIV (Fluzone)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: CSL Limited Influenza Vaccine | Arm Label: 2; Type: OTHER; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: CSL Limited Influenza Vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 6-23 months; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 2-8 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 9-17 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 18-44 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: 45-60 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Arm Label: >60 years; Type: N/A; Interventions: Other: This is non-intervention observational study | Intervention Type: OTHER; Name: This is non-intervention observational study; Assigned to Arm(s): 18-44 years, 2-8 years, 45-60 years, 6-23 months, 9-17 years, >60 years
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: VAX125 | Intervention Type: BIOLOGICAL; Name: VAX125; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: There is today a growing need for culturally adapted initiatives among immigrants to prevent and treat T2D. Others have failed to increase the level of physical activity in this sedate group. The investigators believe this is due to missing assistance and lack of influence from the Pakistani milieu. To improve this, a culturally adapted physical activity will be established in this project in close cooperation with the Pakistanis themselves.

Through this program it is the investigators' goal to increase their physical activity level and prevent lifestyle diseases among Pakistanis in Oslo with a high risk of developing these diseases.


Options:
A: Intervention Type: BEHAVIORAL; Name: Internet and print-based interventions; Assigned to Arm(s): N/A
B: Arm Label: Tailored Physical Activity Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Physical Activity Intervention | Arm Label: No Tailored Physical Activity Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Tailored Physical Activity Intervention; Assigned to Arm(s): Tailored Physical Activity Intervention Group
C: Arm Label: PA intervention and Maintenance plus; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance plus | Arm Label: PA intervention and Maintenance regular; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone based physical activity intervention with maintenance regular | Arm Label: Pedometer; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control (pedometer only) | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance plus; Assigned to Arm(s): PA intervention and Maintenance plus | Intervention Type: BEHAVIORAL; Name: Mobile phone based physical activity intervention with maintenance regular; Assigned to Arm(s): PA intervention and Maintenance regular | Intervention Type: BEHAVIORAL; Name: Control (pedometer only); Assigned to Arm(s): Pedometer
D: Intervention Type: BEHAVIORAL; Name: Physical activity (PA) and immigrants; Assigned to Arm(s): N/A

Answer: D